Abstract
For hypertensive patients with renal diseases (RD), strict blood pressure (BP) control has been recommended in recent hypertension guidelines, such as JNC VI, JNC 7, WHO/ISH 1999 and ESH-ESC 2003. We assessed the current status of BP control and the changes of BP control before and after the publication of these guidelines in 489 hypertensive patients with or without RD (age, 19–89 years, mean 59±13 years) who visited the hypertension and kidney outpatient clinic at Kyushu University Hospital. The clinical characteristics of RD and non-RD patients were assessed (RD patients: age, 20–89 years, mean 60±13 years, n=311; non-RD patients: age, 19–86 years, mean 58±13 years, n=178). In addition, we compared the BP control status in 2003 to that in 1996. In 2003, the BP in RD patients was 134±16/78±10 mmHg and that in non-RD patients was 138±12/83±9 mmHg. When strict BP control was defined as <130/80 mmHg, the frequency of strict BP control in RD patients was 28.9% in 2003. In addition, the BP levels of RD patients in 2003 were significantly lower than those in 1996 (134±16/78±10 mmHg vs. 141±17/85±10 mmHg, p<0.05 for both systolic blood pressure [SBP] and diastolic blood pressure [DBP]), and the frequency of strict BP control in RD patients was higher in 2003 than in 1996 (28.9% vs. 11.8%, p<0.01). The BP levels of non-RD patients in 2003 tended to be lower than those in 1996 (138±12/83±9 mmHg vs. 141±13/85±9 mmHg, n.s.). In 2003, angiotensin II receptor blockers (ARBs) were more frequently prescribed to RD patients than to non-RD patients. Furthermore, the use of ARBs was markedly increased in 2003 compared with 1996. In conclusion, in our outpatient clinic, BP levels in hypertensive patients with RD have improved in recent years, and were lower than those in hypertensive patients without RD, which may in part reflect the physicians' awareness of the importance of strict BP control in RD patients, as suggested by several recent hypertension guidelines.
Similar content being viewed by others
Article PDF
References
Executive summary. Am J Kidney Dis 2004; 43: S16–S41.
Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18.
Locatelli F, Vecchio LD, D'amico M, Andrulli S : Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13: S196–S201.
Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria and the progression of renal diseases. The modification of diet in renal disease study. Ann Intern Med 1995; 123: 754–762.
Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, for the MRFIT Research Group: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. JAMA 1992; 268: 3085–3091.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
Guidelines Subcommittee : 1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–183.
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446.
Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO) International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Ljutic D, Kes P : The role of arterial hypertension in the progression of non-diabetic glomerular diseases. Nephrol Dial Transplant 2003; 18: S28–S30.
Kojima S, Shida M, Yokoyama H : Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27: 379–385.
Agodoa L, Appel L, Bakris G, et al: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001; 285: 2719–2728.
Viberti G, Wheeldon NM, for the Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure–independent effect. Circulation 2002; 106: 672–678.
Perico N, Spormann D, Peruzzi E, Bodin F, Sioufi A, Bertocchi F : Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency. Clin Drug Invest 1997; 14: 252–259.
Brenner BM, Cooper ME, Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Wright JT, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK Trial. JAMA 2002; 288: 2421–2431.
Plum J, Bünten B, Németh R, Grabensee B : Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9: 2223–2234.
Jacobsen P, Andersen S, Jensen BR, Parving HH : Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992–999.
Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM : Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. JRAAS 2003; 4: 43–47.
Segura J, Christiansen H, Campo C, Ruilope LM : How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria? Curr Hypertens Rep 2003; 5: 426–429.
Giri S, Mahajan SK, Sen R, Sharma A : Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency. J Assoc Physicians India 2002; 50: 1245–1250.
Campbell R, Sangalli F, Perticucci E, et al: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094–1103.
Matsuda H, Hayashi K, Homma K, et al: Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res 2003; 26: 875–880.
Levey AS, Coresh J, Balk E, et al: National Kidney Foundation practice guideline for chronic kidney disease, evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–149.
Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR : Hypertension control. Arch Intern Med 2003; 163: 2705–2711.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ohta, Y., Tsuruya, K., Fujii, K. et al. Improvement of Blood Pressure Control in Hypertensive Patients with Renal Diseases. Hypertens Res 30, 295–300 (2007). https://doi.org/10.1291/hypres.30.295
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.30.295
